Biotech Values

[DewDiligence]

Clinical / Regulatory / Litigation Calendar

[Please keep these entries up to date! See
the updating procedure at the end of this post.
Items that are out of date will be removed.]

NOTE: ANYONE MAY UPDATE THIS FILE


Edits: ELN/JNJ/PFE (Bapineuzumab program discontinued—entry deleted).


ABT – Bioresorbable DES: EU launch 2H12 (following reimbursement negotiations—product already approved); US launch possible in 2013 (pending clinical results).

ACHN – See http://investorshub.advfn.com/boards/read_msg.aspx?message_id=75415030 .

AGN – Latisse for androgenetic alopecia: phase-2 data in men and women at unspecified medical conference in 2013.

AMGN – Xgeva sBLA submission for bone health in non-metastatic cancer: 2012-2013 pending results of phase-3 trial in breast cancer.

AMRN – Vascepa (f/k/a AMR101) approved by FDA 7/26/12; decision on NCE status pending.

BIIB – BG-12 for MS: PFUFA date (std review): 12/28/12; MAA pending—no further info available.

BMY – Eliquis in AF: CRL issued 6/25/12—BMY expects to respond in Sep 2011 (according to 2Q12 CC)—no new trials needed; MAA in AF submitted 4Q11—no further info available.
BMY – Eliquis in VTE prevention: approved in EU 3/18/11—commercial launch in most countries by end of 2012; pursuit of this indication in US appears to be dead (http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58061618 ).
BMY – Yervoy phase-3 in 2nd-line CRPC: data mid 2013.

GILD – HCV program (GS-7977, GS-5885): see description of various trials and dates in http://investorshub.advfn.com/boards/read_msg.aspx?message_id=77952062 .
GILD – Quad PDUFA date 8/27/12 (positive FDA panel 5/11/12).
GILD – “Standalone” Evitegravir: NDA submitted 6/27/12, awaiting decision on priority review.
GILD – “Standalone” Cobicstat NDA submitted 6/28/12; MAA submitted 5/23/12.
GILD – GS-7340/’Quad Prime’: Two phase-2 studies ongoing with data in late 2012 or 2013—one tests Quad Prime vs Atripa and one tests Quad Prime vs Prezista + Cobicstat + Truvada.

IDIX – IDX184: start of unspecified all-oral combination studies promised in PR of 6/20/12.
IDIX – IDX719 (NS5A inhibitor): 3-day PoC phase-1b monotherapy data reported 6/20/12; NVS now has exclusive option to license IDX719 with a decision expected in about 3 months.

ITMN – Pirfenidone: No specific timeline for response to FDA’s CRL of 5/4/10 requesting a new trial.

JNJ – Xarelto NDA for VTE treatment/secondary prevention: on or about 11/2/12; (Xarelto NDA in PCI/ACS withdrawn on 7/10/12).

LGND - Promacta for HCV: PDUFA date ~11/30/12 (priority review); MAA submitted 5/30/12.
LGND - SCH527123 (MRK) CXCR2 antagonist p2 COPD is enrolled, data early 2012

MNTA – See http://investorshub.advfn.com/boards/read_msg.aspx?message_id=78179660

NAVB - Lymphoseek (AZD4694) http://navidea.com/about-us/message-from-ceo.html PDUFA date Sept. 10, 2012

PFE – Tofacitinib NDA: PDUFA date is technically 8/21/12, but PFE said on 2Q12 CC that FDA review will take longer.
PFE – Bosutinib in CML: PDUFA date Oct 2012; EU decision mid 2012 (MAA accepted for review 8/17/11).
PFE – Eliquis: see BMY.

SNY – Aubagio for RRMS: original PDUFA date was in June or July but no action yet; in EU, MAA accepted for review 2/23/12.

SPPI - Belinostat phase-3 data: 2012 (according to PR of 3/1/12).

TEVA – Copaxone litigation: see MNTA.
TEVA – Thrice-weekly formulation of Copaxone: timing of NDA unclear according to 6/14/12 PR announcing positive top-line results from GALA study.

VRTX – Phase-2b testing multiple (non-response-guided) protocols for Incivek + VX-222 + ribavirin in treatment-naïve genotype-1 to start 3Q12. (Data on no-IFN arms of ZENITH study reported 2/23/12.)
VRTX – Initial data on studies with ALS-2200 and ALS-2158: 2Q12.

--
Procedure for Updating Calendar

When adding or modifying entries, please follow these steps:

1. Copy the complete text from the old calendar.

2. Make your additions or modifications, inserting new items in alphabetical order.

3. Near the top of the message, list the ticker symbols of the entries you changed (e.g. “Edits: GILD MNTA”).